BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS

摘要

The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with alphavbeta6 integrin inhibition or therapy with TGF-beta pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against alphavbeta6-integrin and/or TGF-beta pathway inhibitors.